• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ABIOMED, Inc. - Common Stock (NQ: ABMD )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ABIOMED, Inc. - Common Stock

    < Previous 1 2 Next >
    FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
    From Abiomed, Inc.
    Via Business Wire
    Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
    Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
    Via MarketBeat
    First Patients in the World Treated with Impella RP Flex with SmartAssist
    From Abiomed, Inc.
    Via Business Wire
    ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
    From Kahn Swick & Foti, LLC
    Via Business Wire
    S&P 500 Component DexCom Set For Further Price, Earnings Growth
    Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
    Via MarketBeat
    Topics Stocks
    Exposures US Equities
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR
    Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to 
    Via Spotlight Growth
    Exposures Product Safety
    ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
    From Abiomed, Inc.
    Via Business Wire
    Johnson & Johnson to Acquire Abiomed
    From Johnson & Johnson
    Via Business Wire
    Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
    From Abiomed, Inc.
    Via Business Wire
    Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
    From Abiomed, Inc.
    Via Business Wire
    MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
    From Abiomed, Inc.
    Via Business Wire
    Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
    From Abiomed, Inc.
    Via Business Wire
    U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
    From Abiomed, Inc.
    Via Business Wire
    Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
    From Abiomed, Inc.
    Via Business Wire
    Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
    From Abiomed, Inc.
    Via Business Wire
    Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
    From Abiomed, Inc.
    Via Business Wire
    Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
    From Abiomed, Inc.
    Via Business Wire
    Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
    From Abiomed, Inc.
    Via Business Wire
    FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
    From Abiomed, Inc.
    Via Business Wire
    TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
    From Abiomed, Inc.
    Via Business Wire
    Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
    From Abiomed
    Via Business Wire
    ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
    From Abiomed, Inc.
    Via Business Wire
    Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
    From Abiomed, Inc.
    Via Business Wire
    Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
    From Abiomed, Inc.
    Via Business Wire
    Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
    From Abiomed, Inc.
    Via Business Wire
    SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
    From Abiomed
    Via Business Wire
    Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
    From Abiomed, Inc.
    Via Business Wire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.